Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Valentina Leta, Peter Jenner, K. Ray Chaudhuri & Angelo Antonini. (2019) Can therapeutic strategies prevent and manage dyskinesia in Parkinson’s disease? An update. Expert Opinion on Drug Safety 18:12, pages 1203-1218.
Read now
Read now
Margherita Torti, Laura Vacca & Fabrizio Stocchi. (2018) Istradefylline for the treatment of Parkinson’s disease: is it a promising strategy?. Expert Opinion on Pharmacotherapy 19:16, pages 1821-1828.
Read now
Read now
F. Javier Álvarez. (2016) Parkinson’s disease, antiparkinson medicines, and driving. Expert Review of Neurotherapeutics 16:9, pages 1023-1032.
Read now
Read now
Aitziber Buqué, Norma Bloy, Fernando Aranda, Isabelle Cremer, Alexander Eggermont, Wolf Hervé Fridman, Jitka Fucikova, Jérôme Galon, Radek Spisek, Eric Tartour, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2016) Trial Watch—Small molecules targeting the immunological tumor microenvironment for cancer therapy. OncoImmunology 5:6.
Read now
Read now
Articles from other publishers (25)
Yuan Zhao, Xin Liu & Guofeng Yang. (2023) Adenosinergic Pathway in Parkinson’s Disease: Recent Advances and Therapeutic Perspective. Molecular Neurobiology 60:6, pages 3054-3070.
Crossref
Crossref
Khaled Radad, Rudolf Moldzio, Christopher Krewenka, Barbara Kranner & Wolf-Dieter Rausch. (2023) Pathophysiology of non-motor signs in Parkinson’s disease: some recent updating with brief presentation. Exploration of Neuroprotective Therapy, pages 24-46.
Crossref
Crossref
Xiaoqin Hu, Jinhuan Ni, Nanyong Gao, Zhize Ye, Guoxin Hu, Jianping Cai & Jianchang Qian. (2022) The effect of CYP3A4 genetic polymorphism and drug interaction on the metabolism of istradefylline. Chemico-Biological Interactions 366, pages 110123.
Crossref
Crossref
Ritam Bandopadhyay, Nainshi Mishra, Ruhi Rana, Gagandeep Kaur, Mohammed M. Ghoneim, Sultan Alshehri, Gulam Mustafa, Javed Ahmad, Nabil. A. Alhakamy & Awanish Mishra. (2022) Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence. Frontiers in Pharmacology 13.
Crossref
Crossref
Elisabet Jakova, Mohamed Taha Moutaoufik, Jeremy S. Lee, Mohan Babu & Francisco S. Cayabyab. (2022) Adenosine A1 receptor ligands bind to α-synuclein: implications for α-synuclein misfolding and α-synucleinopathy in Parkinson’s disease. Translational Neurodegeneration 11:1.
Crossref
Crossref
Shahrul Azmin, Rufaidah Md Rani & Norlinah Mohamed Ibrahim. 2022. Role of Micronutrients in Brain Health. Role of Micronutrients in Brain Health
143
165
.
Sanjay Raghav & Laura D. Perju-Dumbrava. 2022. Techniques for Assessment of Parkinsonism for Diagnosis and Rehabilitation. Techniques for Assessment of Parkinsonism for Diagnosis and Rehabilitation
105
117
.
Muhmmad AtifAbdullah AlsrhaniFarrah NazMuhammad ImranMuhammad ImranMuhammad Ikram UllahAyman A.M. AlameenTanweer Aslam GondalQaisar Raza. (2021) Targeting Adenosine Receptors in Neurological Diseases. Cellular Reprogramming 23:2, pages 57-72.
Crossref
Crossref
Francesco Gentile, Pietro Emiliano Doneddu, Nilo Riva, Eduardo Nobile-Orazio & Angelo Quattrini. (2020) Diet, Microbiota and Brain Health: Unraveling the Network Intersecting Metabolism and Neurodegeneration. International Journal of Molecular Sciences 21:20, pages 7471.
Crossref
Crossref
Ryo Iketani, Shinobu Imai, Hiromasa Horiguchi, Daisuke Furushima, Kiyohide Fushimi & Hiroshi Yamada. (2020) Risk stratification for physical morbidity using factors associated with atypical antipsychotic treatment in Parkinson’s disease: A retrospective observational study using administrative claims data. Journal of Clinical Neuroscience 76, pages 189-194.
Crossref
Crossref
Ajaya Kumar Sahoo, Dhyuti Gupta & Alok Singh. (2020) Istradefylline: a novel drug for ‘off’ episodes in Parkinson’s disease. Drugs & Therapy Perspectives 36:5, pages 208-212.
Crossref
Crossref
Alexandra Kasabova-Angelova, Diana Tzankova, Javor Mitkov, Maya Georgieva, Virginia Tzankova, Alexander Zlatkov & Magdalena Kondeva-Burdina. (2020) Xanthine Derivatives as Agents Affecting Non-dopaminergic Neuroprotection in Parkinson’s Disease. Current Medicinal Chemistry 27:12, pages 2021-2036.
Crossref
Crossref
Roberta Andrejew, Talita Glaser, Ágatha Oliveira-Giacomelli, Deidiane Ribeiro, Mariana Godoy, Alessandro Granato & Henning Ulrich. 2019. Stem Cells. Stem Cells
275
353
.
Maria Rosaria Domenici, Valentina Chiodi, Mirko Averna, Monica Armida, Antonella Pèzzola, Rita Pepponi, Antonella Ferrante, Michael Bader, Kjell Fuxe & Patrizia Popoli. (2018) Neuronal adenosine A2A receptor overexpression is neuroprotective towards 3-nitropropionic acid-induced striatal toxicity: a rat model of Huntington’s disease. Purinergic Signalling 14:3, pages 235-243.
Crossref
Crossref
Angelo Antonini, Elena Moro, Clecio Godeiro & Heinz Reichmann. (2018) Medical and surgical management of advanced Parkinson's disease. Movement Disorders 33:6, pages 900-908.
Crossref
Crossref
Roberto Erro, Francesco Brigo, Stefano Tamburin, Mauro Zamboni, Angelo Antonini & Michele Tinazzi. (2017) Nutritional habits, risk, and progression of Parkinson disease. Journal of Neurology 265:1, pages 12-23.
Crossref
Crossref
Aren van Waarde, Rudi A. J. O. Dierckx, Xiaoyun Zhou, Shivashankar Khanapur, Hideo Tsukada, Kiichi Ishiwata, Gert Luurtsema, Erik F. J. de Vries & Philip H. Elsinga. (2018)
Potential Therapeutic Applications of Adenosine A
2A
Receptor Ligands and Opportunities for A
2A
Receptor Imaging
. Medicinal Research Reviews 38:1, pages 5-56.
Crossref
Crossref
Geoffrey Burnstock. (2017) Purinergic Signalling: Therapeutic Developments. Frontiers in Pharmacology 8.
Crossref
Crossref
Keisuke Suzuki, Masayuki Miyamoto, Tomoyuki Miyamoto, Tomoyuki Uchiyama, Yuka Watanabe, Shiho Suzuki, Taro Kadowaki, Hiroaki Fujita, Takeo Matsubara, Hirotaka Sakuramoto & Koichi Hirata. (2017) Istradefylline improves daytime sleepiness in patients with Parkinson's disease: An open-label, 3-month study. Journal of the Neurological Sciences 380, pages 230-233.
Crossref
Crossref
Dag Aarsland, Byron Creese, Marios Politis, K. Ray Chaudhuri, Dominic H. ffytche, Daniel Weintraub & Clive Ballard. (2017) Cognitive decline in Parkinson disease. Nature Reviews Neurology 13:4, pages 217-231.
Crossref
Crossref
Ali Jazayeri, Stephen P. Andrews & Fiona H. Marshall. (2016)
Structurally Enabled Discovery of Adenosine A
2A
Receptor Antagonists
. Chemical Reviews 117:1, pages 21-37.
Crossref
Crossref
Wolfgang H. Oertel. (2017) Recent advances in treating Parkinson’s disease. F1000Research 6, pages 260.
Crossref
Crossref
Botsakis K, Tondikidou V, Panagopoulos N, Margariti M, Matsokis N & Angelatou F. (2016) Increased sensitivity in the interaction of the dopaminergic/adenosinergic system at the level of the adenylate cyclase activity in the striatum of the “weaver” mouse. Neurochemistry International 99, pages 233-238.
Crossref
Crossref
Dhanya Vijayakumar & Joseph Jankovic. (2016) Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia. Drugs 76:7, pages 759-777.
Crossref
Crossref
Syed Ali, Ning Yin, Arkam Rehman & Verline Justilien. (2016) Parkinson Disease-Mediated Gastrointestinal Disorders and Rational for Combinatorial Therapies. Medical Sciences 4:1, pages 1.
Crossref
Crossref